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Background: Surgical treatment of bone metastases has become increasingly important as patients live longer
with metastatic cancer and one of the main aims is a long-lasting reconstruction which survives the patient.
Conventional osteosynthesis may not be able to achieve this objective in the context of modern day cancer care.
Methods: This study evaluates the oncological outcomes, treatment-related complications, and function after resection
of metastases and reconstruction with modular tumor endoprostheses in 80 patients. All patients who underwent
surgical treatment with modular tumor prostheses for bone metastases from 1993 to 2008 were traced by our
tumor database and clinical information was recorded from patient case.
Results: Mean age was 63 years. The most common primary tumors were renal cell (47%), breast (21%), and lung
(8%). The proximal femur was affected in 45%, proximal humerus in 26%, and the distal femur in 17% of cases. In
22 cases, the tumor prosthesis was implanted during a revision operation. Mean overall survival after surgery was
2.9 years. Overall survival rate was 70% at one year and 20% at five years. Implant survival was 83% after one year
and 74% at five years. Overall rate of operative revision was 18%.
Conclusions: Our data collectively suggest that despite higher costs, implantation of modular tumor
endoprostheses may be a suitable treatment for bone metastases with a low complication rate and rapid
improvement in function in appropriately selected patients.
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Surgical treatment of bone metastases has become in-
creasingly important in view of the longer life expectancy
of patients with metastatic cancer, coupled with advances
in musculoskeletal oncology [1,2]. Estimation of prognosis
and survival is subjective. It has been shown that estima-
tion of survival in cancer patients may be correct only
in 18% and underestimated in 43% of patients [3]. In
addition, current decision-making in metastatic cancer
patients needs to consider not only prognosis and sur-
vivorship, but also quality of life and function [1,4]. The
skeleton is the third most common site of metastases,* Correspondence: jendrik.hardes@ukmuenster.de
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At least every third to fifth patient with cancer develops
bone metastases [1]. One of the most common compli-
cations of long bone skeletal metastases is a pathological
fracture and even though long bones of the extremities
are not the most common site of metastases, long bone
metastases often lead to loss of function, pain, and loss
of ambulation for the patient [2].
Options for surgical management include osteosynthesis
(fixation with an intramedullary nail or plate, in combin-
ation with adjuvants such as bone cement), endoprostheses
(joint replacement prostheses), or tumor endoprostheses
(modular or conventional non-modular components).
Recent advances in musculoskeletal oncology question
the validity of osteosynthesis for surgical palliation of the
cancer patient with bone metastases in today’s context ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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between palliative and curative intent has also shifted, and
the there is growing evidence that local control of metasta-
ses might have a positive impact on prognosis [5]. Surgical
palliation in metastatic bone disease has conventionally
been osteosynthesis with a rigid construct such as an intra-
medullar nail. Ideally, the construct should outlive the pa-
tient, surgery should provide effective and fast pain relief
and ambulation, and there should be an improvement in
survival after surgery, particularly for solitary metastases
[6]. With increased survival of patients with long bone me-
tastases, tumor recurrence, failure of the fixation, and con-
tinuing pain are increasing in incidence and thus the idea
of the osteosynthetic construct surviving the patient may
not be able to keep up with rapid advances in multimodal
treatments which allow patients with bone metastases bet-
ter survival. There has to be a frameshift in thinking with
regards to optimal surgical management of the patient
with metastases, with a greater emphasis on tumor resec-
tion (particularly for solitary metastases) and reconstruc-
tion with longer-lasting options [7,8]. We hypothesize that
compared to conventional osteosynthetic devices, modular
tumor endoprosthetic reconstruction provides early
mobilization, fast relief of pain, and a longer implant
survival in the context of current multimodal and
multidisciplinary treatment despite higher costs, and
may be a more suitable procedure in appropriately se-
lected patients.
Methods
Patient data was retrieved from a prospectively maintained
tumor database from 1993 to 2008. There were 80 pa-
tients (82 surgeries) who underwent long bone metastatic
tumor resection and reconstruction with a modular tumor
MUTARS endoprosthesis (Implantcast GmbH, Buxtehude,
Germany). There were 30 female and 50 male patients,
with a mean age of 63 years ± SD 11.3 (range 34.3 to 83.6).
Mean duration of follow-up was 19 months, ranging from
0.5 to 106.8 months. Two patients were lost to follow-up.
Metastasis in this cohort occurred from 13 different pri-
mary tumors, the most common primaries being renal
cell, breast, and lung (Table 1). In addition, in 4 cases,
the primary tumor remained unknown. Mean duration
from diagnosis to operation was 56 months (range 0.2
to 280.9). There were multiple metastases in 57 pa-
tients. Bone and visceral metastases occurred in 39 pa-
tients (48.8%), multiple bone metastases in 18 patients
(22.5%), and solitary bone metastases in 23 patients
(28.8%). Early metastases (<2 years after index diagnosis)
occurred in 49 of 82 cases (59.8%). Late onset metastases
(2 to 14 years after index diagnosis) occurred in 33 of 82
cases (40.2%). Overall, pathological fractures occurred in
46 patients (56.1%). The most common site of metastasis
was the proximal femur, followed by the proximal humerus(Table 2). Mean duration between first operation and
implantation of the MUTARS tumor endoprosthesis in
these patients was 28 months (range 2 months to
13 years). In the majority of cases we used silver coated
implants (Table 2).
The research has been performed in accordance with
the declaration of Helsinki. As this retrospective analysis
consists of anonymised clinical routine data, the Research
Ethics Committee deems the application for and issue of
an Ethics approval not necessary (Ethics Committee of the
Chamber of Physicians Westfalen-Lippe and the Medical
Faculty of the Westfalian Wilhelms University Muenster,
reference no. 2014-583-f-N).
Statistical analysis was performed using IBM SPSS sta-
tistics version 19.0 (IBM Corporation, Armonk, NY, USA).
Overall survival, event-free survival, and prosthetic sur-
vival was evaluated by Kaplan-Meier survival analysis
(95% confidence interval). Significance was proved
with Kaplan-Meier with log rank tests (level of signifi-
cance <0.05). Estimation of risk was performed using
hazard ratios.
Results
No patient died within the first month after operation.
Overall survival rates were 70% at 1 year post-surgery,
43% at 2 years, 28% at 3 years, and 20% at 5 years (Figure 1).
Mean overall survival was 35.2 ± SD 4.6 months (95% CI,
26.2 to 44.2; range, 1.1 to 154.3 months).
The mean survival rates between tumor types, age, and
gender are shown in the following table. Age and gender
showed no significant influence on overall survival. The
differences in overall survival rates between primary tu-
mors were not statistically significant.
With regards to metastasis site, type of primary, extent
of metastasis, and time between index cancer and de-
tection of metastasis, the survival rates are presented
in Table 3.
Nine patients (11.0%) had a local recurrence after op-
eration; 2 of these 9 patients required a second oper-
ation. Among the local recurrences, 8 patients had renal
cell carcinoma and 1 patient had endometrial carcinoma.
Table 2 Therapy
Operative treatment Prostheses n =82 100%
Type of resection n =77 100.0% Proximal humerus 21 25.6%
Wide 41 53.2% Distal humerus 1 1.2%
Marginal 14 18.2% Total humerus 2 2.4%
Intralesional 22 28.6% Diaphyseal humerus 2 2.4%
Proximal femur 37 45.1%
Adjuvant/neoadjuvant treatment Distal femur 14 17.1%
Local radiotherapy n =48 58.5% Total femur 1 1.2%
Adjuvant 26 Proximal tibia 2 2.4%
Neoadjuvant 13 Diaphyseal femur 1 1.2%
Both 9 Diaphyseal tibia 1 1.2%
Chemotherapy n =29 35.4% Silver coated prostheses 51 62.2%
Preoperative embolization n =13 15.9% Cemented implantation n =72 87.8%
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in our series was 21.6%. After wide resection, the recur-
rence rate was 13.6% and after marginal or intralesional
resection it was 33.3%. Survival of patients with local re-
currence: mean: 22.2 months vs. 36.9 months for pa-
tients without local recurrence (P =0.207).
We defined local progression-free survival as the sur-
vival with the endpoints of local recurrence. Progression
free-survival after operation for the entire cohort was:
mean 34 months ± SD 4.6 (95% CI, 25.0 to 43.2; range,Figure 1 Survival vs. prosthetic survival (months).0.6 to 154.3) and median 19.4 ± SD 2.9 months (95% CI,
13.6 to 25.1). Mean event-free survival in solitary metas-
tasis with wide resection was 41.0 months ± SD 9.6 (95%
CI, 22.2 to 59.8; range, 2.7 to 129.8) and after intrale-
sional resection it was 29.2 ± SD 8.1 months (95% CI,
13.3 to 45.1; range, 2.0 to 51.6) Poorer event-free sur-
vival was observed in patients with chemotherapy or
radiotherapy. For patients without chemotherapy, mean
survival was 38.4 ± SD 7.1 (95% CI, 24.4 to 52.4 months;
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CI, 18.6 to 39.3 months; range, 1.1 to 99.9). Patients
without adjuvant radiotherapy had an event-free survival
of 36.6 ± 6.5 months (95% CI, 23.8 to 49.3 months;
range, 0.6 to 154.3) compared to 28.5 ± SD 5.1 months for
patients with radiotherapy (95% CI, 18.4 to 38.6 months;
range, 1.1 to 106.7).
The overall complication rate in our series was 30.5%.
Out of these, wound healing disturbances comprised 7
patients (8.5%) (chemotherapy and radiotherapy having
no significant influence). Operative wound revision was
necessary in 4 of 7 cases. Loosening of implants (asymp-
tomatic and symptomatic) was observed in 6 patients
(7.3%). Operative revision was required in 4 of 6 cases.
Periprosthetic infection rate was 7.3% (mean 6 months
after operation, proximal femur n =3, distal femur n =2,
diaphyseal tibia n =1, infection rate of silver coated pros-
theses: 3.9% vs. 12.9% in non-silver-coated prostheses,
statistically significant, P =0.041). Operative revision was
required in 4 of 6 cases. Dislocations were seen in 5 pa-
tients (6.1%, proximal humerus n =2, proximal femur n =3).
Transient palsy of radial nerve was observed in 4 cases.
Contracture of the knee joint after implantation of distal
femur occurred in 1 patient. One patient had a peripros-
thetic fracture 2.5 years after implantation of proximal hu-
merus endoprosthesis (Table 4).
The overall revision rate in our series was 18.3%. Overall
median survival in patients who underwent revision sur-
gery was 52.8 ± SD 11.9 months (range, 7.8 to 154.3; 5 year
survival rate, 30.0%). Among patients with no revision sur-
gery, overall median survival was 30.4 ± SD 4.6 months
(range, 1.1 to 129.8; 5 year survival rate, 17.5%) These dif-
ferences were statistically significant (P =0.036; Table 4).
The revision-free prosthetic survival rate (no operative
revision needed) was 83.1% at 1 year, 73.9% at 5 years,
and 47.5% at 8 years. Survival of proximal femur endo-
prostheses was 87.7% at 1 year and at 5 years. Survival of
proximal humerus endoprostheses was 94.7% at 1 year and
75.8% at 5 years. The prosthetic reconstruction outlived the
patient in 92%. We observed a limb survival rate of 98%.Discussion
Studies on tumor prostheses often involve a mixture of
primary sarcomas and metastases, or are focused on a par-
ticular anatomic region such as the proximal femur or hu-
merus. There is a paucity of outcome studies on the use of
modular tumor prostheses in surgical palliation of patients
with long bone skeletal metastases with regards to overall
survival, event-free survival, and survival of prosthesis, re-
gardless of anatomic region. Our data show a mean post-
operative survival of 35 months, which is longer than
most reported survival data on surgical palliation of skel-
etal metastases. The 5-year survival rates we have reported
are high compared to currently available data. Our results
regarding the survival rates with regards to state of metas-
tases support former reports [3,9]. Additionally, our data
show high survival rates even in multiple metastases
(28 months for early-onset multiple metastases, 39 months
for late-onset multiple metastases). Thus, modular tumor
endoprostheses may be an option in surgical palliation of
multiple skeletal metastases as well. In our study, patients
with late onset single metastases had the best survival
(1 year survival rate 91%, 5 year survival rate 29%). This
data is consistent with other studies and thus, in these
cases, a curative surgical approach is justified [10,11].
Most studies show worse survival rates in the context of
skeletal metastases with pathological fractures [10,12,13].
Our data does not support this phenomenon, and we at-
tribute this to a reduction in tumor burden after surgery.
Several authors have reported a higher survival rate after
wide resection of metastases [11,14]. Our data does not
show statistically significant differences in survival be-
tween wide and marginal resections. However, the overall
results of our study support the notion that tumor resec-
tion, which is necessary for modular tumor endoprosthesis
reconstruction, leads to a reduction in tumor volume and
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of view, implantation of a modular tumor endoprosthesis
is a good option in large bony defects, which are often seen
after pathological fractures. However, one must understand
the limitations of this study, including the nonrandomized
and retrospective nature, and therefore the inability to
control some potential confounding variables.
There have been conflicting reports on survival among
patients with local recurrence of skeletal metastases after
surgery. Most studies report lower survival among pa-
tients with local recurrence. However, Utzschneider et al.
[14] reported a higher survival for patients with local re-
currence as patients have to survive a longer time to reach
the point of recurrence; they conclude that tumor recur-
rence might be an indirect indicator for longer survival.
The local recurrence rate among skeletal metastases is
quoted to be between 3 to 20% [15,16]. The incidence of
local recurrence in our study was 11% and most of the tu-
mors that recurred were renal cell carcinomas. Most series
reporting recurrence rates of renal cell carcinomas have
similar numbers to those in our study as renal cell carcin-
oma is not usually radio- or chemosensitive. Our results
showed that patients with local recurrence had a mean
survival of 22 months, whereas patients without local re-
currence had a mean survival of 37 months. However, only
2 patients required revision surgery due to local recurrence.
We believe that resection of metastases and reconstruction
with modular tumor endoprostheses achieves better onco-
logical and functional outcomes in a selected group of pa-
tients as incomplete resection of metastatic lesions is
associated with inadequate relief of pain and higher rates
of local tumor progression.
Besides oncological outcomes, survival of the modular
tumor endoprostheses and the ability of the reconstruc-
tion to ‘outlive’ the patient are key outcome indicators of
successful surgical palliation in these patients. In our
study, 92% of the reconstructions outlived the patient.
The proximal femur and proximal humerus were the
most common sites of reconstruction and high revision-
free survival rates were observed at both locations. In
the proximal femur, endoprosthesis survival rate was
88% after one year and after 5 years. In the proximal hu-
merus, endoprosthesis survival rate was 95% after one
year and 76% after five years. It is known that patients
with bone metastasis have poorer functional outcome
compared to primary tumors as most patients with me-
tastases are older and suffer from other diseases. Com-
pared to Gosheger et al. [17], we achieved almost the
same scores for reconstructions of the proximal humerus
and proximal femur despite the difference of primary vs.
secondary tumors. Complication rates in our series were
consistent with reported outcomes in the literature. With
regards to dislocation of proximal femur endoprostheses,
we achieved a rate of 8% compared dislocation rates of upto 20% in the current literature [18]. Reported revision
rates of secondary tumors are in the range of 3 to 26%
[3,7,8,19,20]. We achieved a revision rate of 18%, and attri-
bute this to a high rate of reoperation (revision of osteo-
syntheses), high incidence of pathological fractures, and a
high proportion of tumors with longer survival (breast,
kidney) in our cohort.
Perhaps the final issue that deserves mention is cost-
effectiveness of surgical treatment of bone metastases,
and as a subset, the justification of increased cost of treat-
ing bone metastases with modular tumor endoprostheses.
Skeletal-related events from bone metastatic disease result
in significant health resource utilization, imposing a sub-
stantial financial burden on health systems. Treatments
that delay or prevent skeletal-related events therefore re-
sult in considerable cost-savings [21]. Singh et al. [22] have
shown that it is more cost-effective to surgically recon-
struct metastases around the hip joint in appropriately se-
lected patients, as compared to the costs of step-down
care in their setting; their patients were predominantly re-
constructed with hip replacement endoprostheses. Ash-
ford et al. [23] reviewed the financial implications of using
proximal femoral replacements for metastatic bone disease
and reported that, in their setting, endoprosthetic replace-
ments were effective treatment but poorly reimbursed
under their funding arrangements. In Germany, public
hospitals get reimbursed for their treatment of patients
according the diagnosis-related group system. These
diagnosis-related groups are assigned based on the
International Classification of Diseases diagnoses, pro-
cedures, and several co-factors. The reimbursement for
modular tumor endoprostheses does not differentiate
between primary bone sarcomas and metastases. There
is currently no homogeneous reliable data on overall
economic effectiveness of the usage of modular endo-
prostheses in metastatic patients in Germany, but infer-
ences can be drawn based the advancements in multimodal
treatment of cancer patients and economic models used
in studies of this nature in other healthcare models
[22,24]. Thus, cost remains a concern and funding ar-
rangements differ from country to country but it seems
intuitive that the cost-benefit ratio is in favor of tumor
resection and replacement with a modular tumor endo-
prosthesis in patients with solitary large, periarticular
metastatic lesions with primary cancers of a favorable
histological subtype and amenable to cure.
To put our data into perspective, the patients who re-
ceived modular tumor endoprostheses for reconstruction
of metastatic disease represent a minority of the overall
number of patients who presented with bone metastases
in our institution. In general, these were patients with
larger, solitary metastatic deposits. An example of such a
case is shown in Figures 2 and 3. In terms of tumor type,
renal cell and breast cancer were the predominant tumor
Figure 2 (A) and (B) Radiographs showing a representative case of a proximal femur metastasis: (A) anterior-posterior and (B) axial
radiograph of the proximal femur of a 76-year-old male patient with a renal cell carcinoma metastasis. The metastasis lead to a
pathological fracture of the proximal femur. An embolization has been performed pre-operatively to reduce intraoperative bleeding (coil visible in
pre-operative radiographs).
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other patients who presented with metastases to our unit
still received an osteosysthesis construct. We refrain from
presenting a selection criterion for endoprostheses versus
osteosynthesis as these decisions are often individualized
and depicting this situation in pure black and white cat-
egories may be an oversimplification and potentially convey
the wrong message to junior musculoskeletal oncologists
climbing the learning curve. For simplicity, resection of
long bone skeletal metastases and replacement with
modular endoprostheses is preferred for large destruc-
tive solitary metastases with primary cancer type/site
that is amenable to cure and/or has been resected with
a curative intent. This is in keeping with data presented
by Ratasvuori et al. [25], who showed that significant fac-
tors in prognosis of en bloc resection of kidney, breast,
prostate, and lung carcinomas include the presence of
organ metastases, overall health status, and disease load.Figure 3 (A) and (B): Radiographs showing the typical post-operative fi
(A) anterior-posterior and (B) axial radiograph of the proximal femur
the fractured proximal femur. Modular proximal femur construct with ceConclusions
Our data collectively suggest that modular tumor endo-
prosthetic reconstruction is a suitable option for surgical
palliation of long-bone skeletal metastases in appropri-
ately selected patients presenting with large tumors and
consequent intralesional resections, recurrences, renal cell
carcinoma, and solitary metastases. The ability of conven-
tional osteosynthetic constructs to outlive the patient with
metastatic cancer should be reevaluated in today’s context
of increased survival as a result of multimodal cancer
treatment coupled with advances in musculoskeletal
oncology as a subspecialty.Consent
All patients signed an informed consent form at hospital
admission allowing the use of anonymized data and im-
ages for research purposes.ndings after reconstruction with a modular tumor endoprosthesis:
of a 76-year-old male patient (see Figure 2) after resection of
mented stem and with cemented Avantage cup (tripolar).
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